Workflow
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
ADMA BiologicsADMA Biologics(US:ADMA) ZACKS·2025-08-07 21:21

Key Takeaways ADMA reported Q2 EPS of 0.15andrevenuesof0.15 and revenues of 122M, both beating consensus estimate.Asceniv drove 29% Y/Y underlying revenue growth, aided by strong adoption and proprietary tech.ADMA reaffirmed 2025+ guidance and sees 1.1B+revenuepotentialbefore2030fromplasmaproducts.ADMABiologics((ADMA)reportedbetter−than−expectedresultsforthesecondquarter.Adjustedearningspershareof15centsbeattheZacksConsensusEstimatebyapenny.Revenuesof1.1B+ revenue potential before 2030 from plasma products.ADMA Biologics ((ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny.Revenues of 122 million (up 14% year over year) a ...